Biogen Inc. (NASDAQ:BIIB) earns a spot on the list of 12 Best Widow and Orphan Stocks to Buy According to Analysts. Jefferies initiates coverage on BIIB with a Buy rating and $190 price target, citing low investor expectations despite strategic and regulatory advancements. Recent developments, including FDA response letters and acquisitions, support a positive outlook on BIIB’s undervalued pipeline. The company focuses on treatments for neurological and neurodegenerative diseases. While BIIB shows investment potential, some AI stocks may offer greater upside and lower risk. For more information on AI stocks, check out Insider Monkey’s report on the best short-term AI stock.

Read more at Yahoo Finance: Jefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PT